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Abstract 
Background: Acquired Immunodeficiency Syndrome is a serious public health problem in Ethiopia. CD4+ T cell 
count testing is the standard method for determining eligibility for antiretroviral therapy. However, automation for 
CD4+ T cell count is not widely available in sub-Saharan Africa including Ethiopia.  
Objective: This study was to determine eligibility for antiretroviral therapy in resource-limited settings using total 
lymphocyte counts, hemoglobin and body mass index among HIV positive patients.  
Materials and methods: CD4+ T cell count was determined using Becton Dickinson FACS count analyzer. Total 
lymphocyte count and hemoglobin concentration were measured by a Cell Dyne 1800 hematology analyzer and body 
mass index was determined. Correlation of total lymphocyte count, hemoglobin and body mass index with CD4+ T cell 
count was determined by Pearson’s correlation coefficient and p-value.  
Results: The correlation between CD4+ T cell count and Total Lymphocyte Count (TLC) was not strong, but the 
association between CD4+ T cell count and TLC was highly significant and correlation between CD4+ T cell counts 
with hemoglobin were very weak.  The sensitivity, specificity, Positive Predictive Value (PPV) and Negative 
Predictive Value (NPV) of TLC using threshold value of 1000 cells/mm3 for CD4+ T cell counts <350 cells/mm3 were 
3% , 94%, 17% and 71%, respectively. Total lymphocyte count threshold of 1750 cells/mm3 were the better predictor 
of CD4+ T cell counts of <350 cells/mm3 when compared to < 200 cells/mm3. 
Conclusion: TLC showed weak correlation with CD4+ T cell counts but the association between CD4+ T cell count 
with TLC was significant (p<0.0001). The TLC threshold of 1750 cells/mm3 were the most accurate predictors of 
CD4+ T cell counts of <350 cells/mm3. Therefore, the significant association of TLC with CD4+ T cell count may 
suggest that TLC could be used as marker for CD4+ T cell count in determining anti-retroviral treatment initiation 
when CD4+ T cell count is not available particularly in rural settings where laboratory facilities are lacking.  [Ethiop. J. 
Health Dev.  2013;27(1):48-54] 
 
Introduction  
Human immunodeficiency virus (HIV) is a member of 
the retroviruses that causes acquired immunodeficiency 
syndrome (AIDS), a condition in humans associated with 
progressive failure of the immune system (1, 2). Human 
immunodeficiency virus infection leads to a state of 
generalized immune activation which leads to increased 
T- cell turnover (production and destruction), increased 
activation-induced death of T- cells, a decline in the size 
of the CD4+ T cell pool and a state of activation- induced 
immunodeficiency. The virus can also mutate and escape 
immune mediated opposition by suboptimal Cytotoxic T 
lymphocytes (CTL) followed by altered functions of the 
antigen presenting cell’s (APCs) that may exhibit 
diminishing ability to elicit immune responses (3). 
 
At the end of 2010, an estimated 34 million people were 
living with HIV worldwide. This reflects the continued 
growth in the number of new HIV infections (2.5 
million) as well as deaths (2.1 million) that were reported 
in the same year (4). In sub-Saharan Africa, the estimated 
numbers of adults and children living with the virus at 
the end of 2010 were 22.5 million, nearly 70% of the 
global cases (4). Based on the 2007 single point estimate, 
the Government of Ethiopia (GOE) projected HIV 
prevalence to be 2.4% in 2010. The 2011 Ethiopia 
Demographic and Health Survey (EDHS) data showed 
that the urban adult HIV prevalence was 4.2 percent and 
rural adult HIV prevalence was 0.6 percent (5). In the 
Amhara National Regional State of Ethiopia, the 
prevalence of HIV among adults in 2010 was reported to 
be 2.7 % (6). 
 
The WHO guidelines for ART initiation in low-income 
countries state that HIV-infected individuals should start 
ART when they have WHO stage IV disease, stage III 
disease and a CD4+ T cell count of <350 cells/mm3, or 
stage I or II disease with CD4+ T cell count <200 
cells/mm3 (7). Recently WHO has recommended 
increasing this threshold for stages I and II to 350 
cells/mm3 (8). 
 
The proportion of ART patients that had CD4 count was 
19.9% and 18.2% by the year 2003 in Ethiopia and the 
Amhara Region, respectively. Despite that, the 
proportion of ART patients that had CD4 count increased 
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to 68.6% by the year 2005 in the country (9).  Although 
CD4+ T cell count is commonly used to determine ART 
initiation, the WHO guidelines recommend the use of 
clinical staging alone or in combination with total 
lymphocyte counts (TLCs) of < 1200 cells/mm3 in order 
to determine ART eligibility (7). However, many studies 
have found both clinical stages III/IV and the TLC 
threshold to have poor sensitivity for low CD4+ T cell 
counts, leading researchers attempt to define other TLC 
thresholds which better correspond to CD4+ T cell counts 
of < 200 or 350cells/mm3 (10-12). 
 
Studies which have incorporated hemoglobin (Hgb) or 
haematocrit into clinical algorithms have shown 
improved performance of TLC in predicting low CD4+ T 
cell counts (13-15). However, such studies have treated 
the CD4+ T cell count threshold as an absolute standard, 
where initiating treatment in patients with CD4+ T cell 
counts above 200 cells/mm3 is undesirable. As delaying 
ART until CD4+ T cell counts fall below 200 cells/mm3 
results in increased mortality (16) and most studies from 
sub-Saharan African settings have shown high mortality 
rates in the first year of therapy (17-19), it seems 
reasonable to adopt the more liberal ART eligibility 
criteria of <350 cells/mm3.  The laboratory determination 
of the CD4+ T cell count requires the use of a 
fluorescence-activated Cell-Sorter (FACS) flow-
cytometer that makes the process both expensive and 
labor-intensive. In terms of comparative costs, a single 
CD4+ T cell count may be 30–50 times more expensive 
than a complete blood cell count (20). Determining total 
lymphocyte count, hemoglobin concentration and BMI 
are inexpensive to measure and do not require advanced 
technology.  However, there is no sufficient information 
concerning the correlation of TLC, Hgb and BMI with 
CD4+ T cell counts in the study area in particular and in 
Ethiopia in general. Nevertheless, Abuye et al. reported 
that CD4 counts were independently associated with BMI 
among HIV-negative Ethiopians. They also concluded 
that low BMI among Ethiopians may have contributed to 
their overall low CD4 count (21). 
 
The present study was designed to investigate the 
eligibility of antiretroviral therapy in resource-limited 
settings using total lymphocyte counts, hemoglobin and 
body mass index. 
 
Methods  
A hospital-based cross-sectional study was conducted at 
University of Gondar Hospital. At the time of the study 
the hospital gives pre-antiretroviral therapy to 3000 HIV 
positive patients. In this study, only adult patients under 
pre-ART follow up were included. However, pregnant 
women, smokers, patients with tuberculosis, malaria and 
acute viral infections were excluded. Using a pretested 
and structured check list, information on sex, age, marital 
status, level of education, occupation, TB, diarrhea, and 
WHO stages of HIV were assessed. The data were 
completed by face-to-face interview.  Five milliliters of 
venous blood was collected from each study subject 
using disposable tubes for routine laboratory 
investigation. The left over samples were used for this 
study but a written informed consent was taken from 
each patient during collection of the socio-demographic 
information. Blood samples were collected under aseptic 
conditions between 8:00 and 10:00 am and analyzed 
within an hour by mixing with Ethylene Diamine-Tetra-
Acetic Acid (EDTA) anticoagulant for five minutes. The 
hemoglobin concentration and total leukocyte count 
(TLC) were determined using Cell Dyne 1800 
hematology analyzer (Abbott Cell Dyne Operators 
manual). From the same blood samples, a CD4+ T cell 
count was enumerated using BD FACS count (BD 
Biosciences instrument user’s guide) following the 
manufacturer’s instructions. 
 
All study subjects were assessed for malnutrition using 
body mass index (BMI) (22).  The reliability of the study 
findings were guaranteed by implementing quality 
control (QC) measures throughout the whole process of 
the laboratory work. All materials, equipment and 
procedures were adequately controlled. FACS count (BD 
Biosciences instrument user’s guide) and Cell Dyne 1800 
(Abbott Cell Dyne Operators manual) were checked for 
linearity and validity by using quality control reagents. 
Pre-analytical, analytical and post-analytical stages of 
quality assurance that were incorporated in Standard 
Operating Procedures (SOPs) were strictly followed. 
Appropriate volume of blood and anticoagulant were 
used to maintain the specimen’s quality. Every day 
before the samples were investigated, control reagents 
with low, medium and high concentration were 
simultaneously investigated by the Cell Dyne 1800 and 
FACS count machines to maintain the reagents quality. 
 
The data was entered, cleaned and analyzed using SPSS 
statistical computer software version 20. Pearson’s 
correlation coefficient, sensitivity, specificity, positive 
and negative predictive values and a Receiver Operating 
Characteristic (ROC) curve were used for statistical 
analysis to determine the association between TLC, 
hemoglobin concentration and BMI with that of CD4+ T 
cell count.  A p-value of less than 0.05 was considered as 
statistically significant. Ethical approval was obtained 
from the University of Gondar, School of Biomedical and 
Laboratory Sciences Ethical Clearance Committee before 
going ahead with the study. Each study participant was 
asked to participate voluntarily. When the study 
participants agreed to participate, written informed 
consent was obtained from each of them. Each study 
participant was informed about the objective of the study 
which was to contribute to the improvement and to look 
for alternative evaluation method to initiate anti-
retrovirus treatment for poor patients in resource poor 
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health facilities. Voluntary participation and the right to 
withdraw at any time were emphasized. 
 
Results  
Socio-demographic Characteristics:   
A total of 341 pre-ART HIV positive patients were 
recruited for the present study. One hundred twenty-three 
patients (36.1%) were males and 218 (63.9%) were 
females. The median age of the study participants was 30 
years (IQR=26.5-38.5) and the majority (75.6 %) were 
living in urban settings. Three hundred eight (90.3%) of 
the participants were Orthodox Christians and data on 
marital status showed that 158 (46.3%) were married 
(Table 1). 
 
Table 1: Socio-demographic Characteristic of HIV Positive Study Participants at the University of Gondar Hospital, 
Northwest Ethiopia, 2012 
Characteristic  Male N (%) Female N (%) Total N (%) 
Age (yrs)  
 
 
18-29 31 (22) 107 ( 78) 138 (40.5) 
30-39 53 (41) 75 59) 128 (37.5) 
40-49 28 (58) 20 (42) 48 (14) 
≥50 11 (41) 16 (59) 27 (8) 
Residence  Urban 89 (34.5) 169 (65.5) 258 (75.6) 
Rural 34 (40.9) 49 (59.1) 83 (24.4) 
Marital status   Single 34 (66.7) 17 (33.3) 51 (15) 
Married 64 (40.5) 94 (59.5) 158 (46.3) 
Divorced 22 (24.7) 67 (75.3) 89 (26.1) 
Widowed 2  (5.9) 32 (94.1) 34 (10) 
Separated 1 (11.1) 8 (88.9) 9 (2.6) 
  Religion  
 
 
Orthodox 112 (36.4) 196 (63.6) 308 (90.3) 
Muslim 10 (37.1) 17 (62.9) 27 (7.9) 
Protestant 0 2 (100) 2 (0.6) 
Catholic 1 (25) 3 (75) 4 (1.2) 
  Occupation  Merchant 19 (35.2) 35 (64.8) 54 (16) 
Civil servant 29 (54.7) 24 (44.3) 53 (15.5) 
House wife 0 61 (100) 61 (17.9) 
Student 2 (13.3) 13 (86.7) 15 (4.4) 
Farmer 15 (53.5) 13 (46.5) 28 (8.2) 
Driver 9 (100) 0 9 (2.6) 
Daily laborer 38 (41.7) 53 (58.3) 91 (26.6) 
Private 11 (40.9) 19 (59.1) 30 (8.8) 
Educational status Illiterate 25 (23.8) 80 (76.2) 105 (30.8) 
Elementary school 48 (44) 61 (56) 109 (32) 
High school 31 (36) 55 (64) 86 (25.2) 
Certificate 1 (10) 9 (90) 10 (2.9) 
Diploma 14 (56) 11 (44) 25 (7.1) 
Degree and above 4 (66.7) 2 (33.3) 6 (2) 
Total 123 (36.1) 218 (63.9) 341(100) 
 
Immuno-hematological Profiles of the Pre-ART HIV 
Positive Patients:   
The median CD4+ T cell count and total lymphocyte 
count (TLC) were 342 cells/mm3 (IQR=212-496) and 
2000 cells/mm3 (IQR=1500-2600), respectively. The 
median hemoglobin (Hgb) concentration and body mass 
index (BMI) were 13.1 g/dl (IQR=11.6-14.1) and 20.1 
kg/m2 (IQR=18.3-22.6), respectively (Table 2). 
 
In this study, 83 (24.3%) of the study participants had 
CD4+ T cell counts of <200 cells/mm3, 96 (28.2%) of 
them had CD4+ T cell counts between 200 to 350 
cells/mm3 and the rest (47.5%) had > 350 cell/mm3. Forty 
eight (14.1%) of the study participants had total 
lymphocyte counts (TLC) of <1200 cells/mm3. On the 
other hand, 103 (30.2%) study participants had 
hemoglobin concentrations of <12g/dl and 91(26.7%) of 
them had body mass index of <18.5 kg/ m2. Fifty two 
(62.7%) participants had total lymphocyte counts of 
>1200 cells/mm3 with CD4+ T cell counts of <200 
cells/mm3 (Table 3). 
 
Correlation of Total Lymphocyte Count, Hemoglobin 
and Body Mass Index with CD4+ T Cell Count:   
Correlation between CD4+ T cell count and TLC (n=341) 
(r=0.425) was not strong, but the association between  
 
Table 2: Immuno-hematological profiles and body mass index of the study participants at University of 
Gondar Hospital, Northwest Ethiopia, 2012 
 N Minimum Maximum Median         IQR Mean St Dev. 
Hemoglobin  341 5.80 18.30 13.1 11.6-14.1 12.8 1.9 
Total lymphocyte counts  341 500.0 5220.00 2000 1500-2600 2127.6    908.4 
CD4+ T cell counts  341 13.00 1103.00 342 212-496 367.4 214.2 
Body mass Index 341 12.32 33.60 20.1 18.3-22.6 20.6     3.4 
IQR-Inter quartile range 
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CD4+ T cell count and TLC was significant 
(p<0.0001)and correlation between CD4+ T cell count 
with hemoglobin (r=0.188, p=0.0005) was very weak.  
Moreover, there was no significant correlation between 
BMI and CD4+ T cell count. The Positive Predictive 
Value (PPV) for CD4+ T cell count of <200 cells/mm3 
using a threshold value of 1000 cells/mm3 for TLC was 
78%, while the sensitivity was only 17%. The Negative 
Predictive Value (NPV) was 79%, with 98% specificity. 
The sensitivity, specificity, PPV and NPV of TLC using 
a threshold value of 1000 cells/mm3 for CD4+ T cell 
count of <350 cells/mm3 were 3% , 94%, 17% and 71%, 
respectively (Table 4). A TLC threshold value of 1200 
cells/mm3 with CD4+ T cell count of <200 cells/mm3 
gave a sensitivity of 25% and a specificity of 97%. A 
TLC threshold of 1750 cells/mm3produced sensitivity, 
specificity, PPV, and NPV  of 65%, 69%, 4%, and  86%, 
respectively with  an accuracy of 79% for CD4+ T cell 
count of <200 cells/mm3. Initiation of ART to all HIV 
positive participants with a TLCs of ≤ 2250 cells/mm3 
produced a sensitivity of 82% for CD4+ T cell count of 
<200 cells/mm3 (Table 4). 
Table 3: Distribution of Immuno-hematological profiles and Body mass index of study participants by CD4+ T cell 
count strata at University of Gondar Hospital, Northwest Ethiopia, 2012 
 CD4+  T cell count/mm3 Total 






TLC/mm3 ≤1200 29(34.9) 15(15.6) 4(14.1) 48(14.1) 
1200-3500 52(62.7) 77(80.2) 138(85.2) 267(78.3) 
>3500 2(2.4) 4(4.2) 20(12.3) 26(7.6) 
Hgb  g/dl ≤12 39(47.0) 23(24.0) 41(25.3) 103(30.2) 
12-18 44(53.0) 72(75) 121(74.7) 237(69.1) 
>18 0 1(1) 0 1(0.3) 
BMI Kg/m2 <18.5 32(38.6) 27(28.1) 32(19.8) 91(26.7) 
18.5-25 49(59.0) 60(6.5) 105(64.8) 214(62.8) 
>25 2(2.4) 9(9.4) 25(15.4) 36(10.6) 
Total  83(24.3) 96(28.2) 162(47.5) 341(100) 
 
Table 4: Sensitivity, specificity and predictive values of TLCs alone or in combination with Hgb and BMI in predicting CD4+ T 
cell counts ≤200cells/mm3 and ≤350cells/mm3 at University of Gondar Hospital, Northwest Ethiopia, 2012 






CD4+ T cell count ≤200cells/mm3 CD4+ T cell count ≤350cells/mm3 
Sen. Sp PPV NVP ACC Sen. SP PPV NVP ACC FP 
 CD4 alone 1.00 1.00 1.00 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0 
TLC alone 
1000    0.17 0.98 0.78 0.79 0.79 0.03 0.94 0.17 0.71 0.68 0.02 
1200    0.25 0.97 0.72 0.80 0.79 0.08 0.91 0.21 0.75 0.67 0.04 
1500    0.48 0.84 0.49 0.83 0.75 0.28 0.78 0.33 0.73 0.64 0.16 
1750    0.65 0.69 0.4 0.86 0.79 0.50 0.65 0.36 0.77 0.61 0.31 
2000    0.74 0.58 0.36 0.87 0.62 0.64 0.56 0.36 0.80 0.58 0.42 
2250    0.82 0.43 0.32 0.88 0.52 0.78 0.43 0.35 0.83 0.53 0.57 
2500    0.87 0.36 0.30 0.89 0.48 0.86 0.37 0.35 0.87 0.51 0.64 
2750    0.92 0.24 0.28 0.90 0.70 0.91 0.25 0.32 0.87 0.43 0.76 
3000    0.93 0.18 0.02 0.89 0.36 0.92 0.18 0.31 0.85 0.39 0.82 
3500    0.96 0.11 0.26 0.90 0.31 0.95 0.10 0.29 0.83 0.34 0.90 
Hemoglobin alone  
  12  0.47 0.28 0.38 0.77 0.70 0.28 0.81 0.70 0.41 0.60 0.19 
TLC combined with Hgb and/or BMIs 
1750 2750 11 18 0.04 0.97 0.30 0.76 0.75 0.04 0.98 0.4 0.72 0.71 0.03 
1750 2750 12 18 0.05 0.97 0.31 0.76 0.74 0.04 0.96 0.31 0.72 0.70 0.05 
1750 2750 11  0.05 0.96 0.33 0.72 0.70 0.05 0.96 0.27 0.76 0.74 0.04 
1750 2750 12  0.08 0.92 0.24 0.76 0.71 0.08 0.91 0.28 0.72 0.68 0.09 
2000 3000 11  0.01 0.96 0.09 0.75 0.73 0.04 0.97 0.36 0.72 0.70 0.04 
2000 3000 12  0.04 0.92 0.13 0.75 0.71 0.05 0.93 0.22 0.71 0.68 0.08 
2000 3000  18 0.06 0.93 0.22 0.76 0.72 0.08 0.94 0.35 0.72 0.70 0.07 
2000 3000 11 18 0.04 0.99 0.50 0.76 0.76 0.03 0.99 0.50 0.72 0.72 0.01 
NB: Body Mass Index=Weight (Kg)/Height (m2), Sen. -Sensitivity, SP =Specificity, 
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The peripheral blood absolute CD4+ T cell count and 
CD4+ T cell proportion are among the surrogate markers 
for the assessment of the risk for progression to AIDS in 
HIV-infected individuals. They are clinically useful in 
assessing the risk of developing certain AIDS-related 
opportunistic infections and for timing the initiation of 
antiretroviral and prophylactic antimicrobial therapies 
(23). The median CD4+ T cell count and the total 
leukocyte count observed among HIV-positive patients in 
Gondar (342 cell/mm3 and 2000 cell/mm3) were 
relatively similar to the reports of a similar study from 
Uganda, which were 239 cells/mm3 and 1830 cells/mm3, 
respectively (24). One of the possible reasons for the 
difference between the findings of these two studies 
could be the delay in time during laboratory 
investigations. However, the median CD4+ T cell count 
in the present study (342 cells/mm3) was lower than the 
finding in the study from Brazil (430 cells/mm3), but the 
median TLC (1900 cells/mm3) was almost comparable 
(22). On the other hand, lymphocyte counts reported for 
adults from the Central African Republic were 
significantly higher than those found in studies conducted 
in Ethiopia (25). The difference and/or discrepancies 
observed on CD4+ T cell count among different 
population groups could be because of the different 
ethnic and socioeconomic factors that can influence 
difference in immune-hematological profiles. 
 
The proportion of HIV positive patients that had CD4+ T 
cell counts of <200 cells/mm3 and CD4+ T cell counts of 
<350 cells/mm3 in the present study were 24.3% and 
52.5%, respectively. This was by far different from a 
similar report from Indonesia, where 66% had CD4+ T 
cell counts of <200 cells/mm3 and 81% had <350 
cells/mm3 (26). However, in the present study, 
tuberculosis patients, pregnant mothers, WHO clinical 
stage IV patients and smokers, were excluded. 
Previously, Irwin had reported low CD4+ T-cell counts 
associated with a variety of conditions, including many 
viral infections, bacterial infections, parasitic infections, 
sepsis, tuberculosis, coccidioidomycosis, burns, trauma, 
and intravenous injections of foreign proteins, 
malnutrition, over-exercising, pregnancy, normal daily 
variation, psychological stress, and social isolation (27-
29). 
 
In the present study, CD4+ T cell counts were slightly 
correlated with TLC and the association was strong and 
significant (<0.0001). Recently, Githinji et al. from 
Kenya reported that TLC and CD4 counts were 
positively correlated in children with severe immuno-
suppression because of HIV-1 infection (30). In addition, 
according to reports from China the correlation between 
CD4+ T cell counts with TLC was found to be 
statistically significant (31). Strong correlation between 
CD4+ T cell counts and TLC was also reported in India 
(32), Indonesia (26), Iran (33) and England (34). 
However, Daka and Loha from the Southern Ethiopia 
reported low sensitivity and specificity of TLC as a 
surrogate measure of CD4 counts (35).  Low correlation 
between CD4+ T cell counts with hemoglobin was found 
in the present study. Correlation of hemoglobin 
concentration with CD4+ T cell count was not also 
significant in a study from Iran and China (33, 36). 
Correlation between CD4+ T cell counts with BMI was 
not also statistically significant in the present study. This 
was also supported by other similar studies in Uganda 
and Indonesia that reported no significant correlation 
between CD4+ T cell count and BMI (24, 26). However, 
it is believed that malnutrition reduces body weight, 
depletes energy stores, brings about loss of somatic 
protein (low muscle mass) and low levels of serum 
albumin, transfer in, pre-albumin and other visceral 
proteins (37). Nutritional deficiency has a major impact 
on immune function which may result in depression of 
lymphocyte count or function that are not desirable in an 
individual fighting invasive infection. 
 
The WHO guidelines for ART initiation in low-income 
countries state that HIV-infected individuals should start 
ART when TLC is ≤1200 cells/mm3 or CD4+ T cell count 
is <200 cells/mm3 (8). In the present study, pre-ART HIV 
positive study participants with CD4+ T cell count of 
<200 cells/mm3 that had TLCs of ≤1200 cells/mm3 
demonstrated a sensitivity of 25%; specificity=97%; 
PPV=72% and NPV=80%. Previous reports from India 
showed that pre-ART HIV positive study subjects having 
TLC of ≤1200 cells/mm3 had a sensitivity of 70.3%, 
specificity of 95%, PPV of 89.7% and NPV of 84.9% for 
predicting CD4+ T cell count of <200 cells/mm3 (26). 
This finding indicated that taking similar CD4+ T cell 
count and TLC among different population groups 
resulted in different sensitivity, specificity, positive 
predictive value and negative predictive values for 
initiating anti-retroviral therapy among HIV positive 
patients.  The specificity, PPV and NPV of the present 
study were comparable with other studies, even though 
the sensitivity was found to be lower. The difference in 
sensitivity could be attributed to differences in factors 
related to: immuno-hematology, socioeconomic, 
biological, feeding habit, and even the virus species that 
caused the disease within the different population groups.  
HIV-1 is more virulent and more infective than HIV-2 
(38).  HIV-1 subtype C virus was reported to be the main 
strain in HIV infection in Ethiopia as well as in Eeastern 
and Southern Africa (37). 
 
Eligibility for ART to all participants with a TLCs of ≤ 
1750 cells/mm3 produced the most accurate predictor of 
CD4+ T cell count of <200 cells/mm3 giving an accuracy 
of 79% (95% CI: 69-80). On the other hand treatment 
initiation for all patients with a TLC of <2000 cells/ mm3, 
excluded all patients with a TLC of >3000 
cells/mm3.Threrefore, the use of hemoglobin 
concentration and BMI values for those patients with 
TLC of between 2000 cells/mm3 and 3000cells/mm3 
might help determine eligibility for ART. In a study 
conducted in Uganda, Moore et al. reported that 
treatment algorithms with a TLC of < 2000 cells/mm3 
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excluded all patients with a TLC of > 3000 cells/mm3. 
They used hemoglobin and/or BMI values to determine 
eligibility for those with TLC values between 2000 to 
3000 cells/mm3 that marginally improved accuracy (23). 
Moreover, Gautam et al. (24) showed that low 
hemoglobin concentration values and low BMI are 
independent risk factors for HIV disease progression. 
Therefore, we suggest that incorporating hemoglobin 
concentration and BMI into the ART eligibility criteria 
could be valuable but it requires additional studies. 
Moreover, the present study demonstrated that using a 
TLC of 2250 cells/mm3 to determine ART eligibility in 
subjects with WHO clinical stages I, II or III, could 
identify 82% of subjects with CD4+ T cell count of <200 
cells/mm3, while 57% of subjects eligible for  ART 
would have CD4+ T cell counts of > 200 cells/mm3.  This 
is supported by other studies reporting that offering ART 
to all subjects with TLC of less than 2250 cells/mm3 
produced a sensitivity of 88% (23). 
 
The laboratory investigation method used in this study 
was only CD4+ T cell count which is not the only perfect 
predictor of the severity of viral infection among HIV 
positive patients. The gold standards for determining 
eligibility for ART are both determining viral load, which 
measures the severity of viral infection, and CD4+ T cell 
count. The proportion of HIV positive study subjects 
with CD4+ T cell counts of < 200 cells/mm3 and < 350 
cells/mm3 in the present study was not very high: 83 
(24.3%) and 179 (52.5%), respectively resulting in a 
large number of subjects being not ART-eligible: 162 
(47.5%).In conclusion, although the TLC showed weak 
correlation with CD4+ T cell counts, the association 
between CD4+ T cell count and TLC was significant 
(p<0.0001). The correlation between Hgb and CD4+ T 
cell counts was weaker and there was no correlation 
between BMI and CD4+ T cell counts. Eligibility for 
ART of all participants with TLCs of ≤ 1750cells/mm3 
produced the most accurate predictor of CD4+ T cell 
count of <350 cells/mm3 giving an accuracy of 79% and 
initiation of ART to all HIV positive participants with a 
TLCs of ≤ 2250 cells/mm3 produced a sensitivity of 82% 
for CD4+ T cell counts of <200 cells/mm3. Therefore, 
although weak, the significant association of TLC with 
CD4+ T cell count may suggest the possibility that TLC 
could be used as marker for CD4+ T cell count in 
determining anti-retroviral treatment initiation when 
CD4+T cell count is not available particularly in rural 
settings where laboratory facilities are lacking.  Further 
studies are also suggested to confirm the relationships 
using larger sample size. 
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